233
Views
16
CrossRef citations to date
0
Altmetric
Ovary

Metabolomics in serum of ovariectomised rats and those exposed to 17β-oestradiol and genistein

, , , , , & show all
Pages 760-767 | Received 03 Feb 2010, Accepted 15 Apr 2010, Published online: 26 May 2010
 

Abstract

Objective. Metabolites profiling provides global insights in characterisations and interactions of metabolites under specific physiological or pathologic states. The aim of this study was to examine serum metabolic changes in bilateral ovariectomised (OVX) rats and those exposed to 17β-oestradiol (E2, 30 μg/kg bw, sc.) or genistein (50 μg/kg bw, sc.) for 12 weeks.

Methods. Serum samples were detected by ultra-performance liquid chromatography-quadrupole time-of-flight mass spectrometry (UPLC-q-TOF-MS). Significant variables were found by the orthogonal partial least-squares analysis and identified by matching their tandem MS fragmentation patterns with reference standards.

Results. There were 54 variables changed in OVX group compared with sham group. Genistein might induce more intensive changes of metabolites than E2 in OVX rats. Among the 54 significant variables of OVX group, 8 and 20 were found to be affected by E2 and genistein, respectively. Finally, four of them were identified as arachidonic acid (AA), eicosapentaenoic acid (EPA), ergocalciferol and cholecalciferol. Both E2 and genistein could reverse levels of AA, EPA and ergocalciferol to sham levels. Only genistein treatment could reverse the level of cholecalciferol.

Conclusions. This study provided a serum profile of ovary dysfunction and showed some similarities and differences between E2 and genistein treatments of the OVX model.

Acknowledgements

This work is supported by the Science and Technology Committee of Shanghai (06jc14083, 09XD1405600), Shanghai Leading Academic Discipline Project (B906), National Science Foundation of China (No. 30800908 and 30725045), NCET Foundation and National 863 Program (2006AA02Z338). All authors approved the final manuscript. All authors declared that they had no conflict of interest.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.